Insider · CIK 0001821189
Nello Mainolfi
Files at KYMR (Kymera Therapeutics, Inc.). First filing Jun 3, 2025, latest Oct 1, 2026.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
KYMR: Kymera Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | Kymera Therapeutics, Inc. | $3.4M 30,000 shares | -4% | +101% from low-14% from high | |
| 30Weak | Kymera Therapeutics, Inc. | $1.5M 30,000 shares | -4% | +107% from low-17% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | KYMR Kymera Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +30,000 | $2.08 | $62k | 696,568 | 11 d ago |
| Oct 1, 2026 | KYMR Kymera Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -3,525 | $111.44 | $393k | 693,043 | 11 d ago |
| Oct 1, 2026 | KYMR Kymera Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -5,506 | $112.42 | $619k | 687,537 | 11 d ago |
| Oct 1, 2026 | KYMR Kymera Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -4,876 | $113.24 | $552k | 682,661 | 11 d ago |
| Oct 1, 2026 | KYMR Kymera Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -7,601 | $114.43 | $870k | 675,060 | 11 d ago |
| Oct 1, 2026 | KYMR Kymera Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -8,230 | $115.40 | $950k | 666,830 | 11 d ago |
| Oct 1, 2026 | KYMR Kymera Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -262 | $116.12 | $30k | 666,568 | 11 d ago |
| Oct 1, 2026 | KYMR Kymera Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -30,000 | $0.00 | $0 | 60,000 | 11 d ago |
| Jun 3, 2025 | KYMR Kymera Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +30,000 | $2.08 | $62k | 690,482 | Jun 3, 2025 |
| Jun 3, 2025 | KYMR Kymera Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -30,000 | $49.00 | $1.5M | 660,482 | Jun 3, 2025 |
| Jun 3, 2025 | KYMR Kymera Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -30,000 | $0.00 | $0 | 465,559 | Jun 3, 2025 |
| Mar 3, 2025 | KYMR Kymera Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +365,000 | $0.00 | $0 | 365,000 | Mar 3, 2025 |
| Jan 10, 2025 | KYMR Kymera Therapeutics, Inc. | MOption exercise Common Stock | +10,000 | $2.08 | $21k | 659,959 | Jan 13, 2025 |
| Jan 10, 2025 | KYMR Kymera Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative | +10,000 | $0.00 | $0 | 495,559 | Jan 13, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.